Psilocybin Given Before Chemotherapy Prevented Nerve Pain in Mice — a Human Trial Starts Next Month
A study published Sept. 3 in Science found that giving mice a dose of psilocybin before chemotherapy prevented much of the nerve damage and lasting pain that platinum-based drugs like cisplatin commonly cause — without blunting the chemo's effect on the tumors themselves. Mice given chemo alone stayed hypersensitive to pain for at least four months afterward; one dose of psilocybin beforehand cut that to about three months, and two doses given a week apart eliminated the hypersensitivity entirely, according to the MD Anderson Cancer Center team behind the work.
"The idea, instead of trying to put things back together that are broken, is to jump in and protect it from the very beginning," says study co-author Patrick Dougherty, a pain researcher at MD Anderson. Follow-up lab work suggests the mechanism may hold in human nerve cells too — psilocybin blocked cisplatin's disruption of mitochondrial transport inside neurons grown in a dish.
This is mouse and cell-culture data, not a human result yet, and it's worth being precise about that distinction. Cornell neuroscientist Alex Kwan, who wasn't involved in the study, called the effect "quite incredible" but said he'd want more data before drawing conclusions about people; University of Sydney neuroscientist Susanna Park raised a similar caution, noting a "large gap" in this field generally "between success in preclinical models and translation to effective therapies for humans." MD Anderson plans to launch a phase 2 trial next month testing psilocybin in roughly 80 patients undergoing chemotherapy for breast, colorectal, or head and neck cancer — the same phase-by-phase process we've broken down in detail before, and one that typically takes years to produce a definitive answer.
One detail for patients who'd rather not trip during cancer treatment: the same team tested an experimental, non-hallucinogenic psilocybin-like compound and found it replicated some of the protective effects in mice.
This is science reporting, not medical advice. Psilocybin remains a Schedule I substance in the US and is not an approved treatment for chemotherapy-induced nerve pain — this specific protective effect has so far only been demonstrated in mice and isolated cells, not people.